rs1799889 — SERPINE1 PAI-1 4G/5G Promoter

PAI-1 4G/5G — The Fibrinolysis Dial in Cardiovascular and Thrombotic Risk

The body dissolves blood clots through a process called fibrinolysis, which depends on tissue plasminogen activator (tPA) converting plasminogen into plasmin — the enzyme that breaks down fibrin clots. Plasminogen activator inhibitor-1 (PAI-1), encoded by the SERPINE1 gene, is the primary brake on this system. When PAI-1 levels are high, tPA is blocked, fibrinolysis is suppressed, and clots persist longer. The rs1799889 variant sits in the SERPINE1 promoter, acting as a molecular dimmer switch: one version drives higher PAI-1 expression, the other lower. This makes it one of the most-studied genetic determinants of clot resolution, cardiovascular risk, and thrombotic pregnancy complications.

The Mechanism

The rs1799889 polymorphism corresponds to a single guanosine insertion/deletion in a run of guanosines in the SERPINE1 promoter, approximately 675 base pairs upstream of the transcription start site. On the GRCh38 plus strand, the G allele represents the 4G variant (four consecutive guanosines) and the A allele represents the 5G variant (five consecutive guanosines). The 4G allele binds only a transcriptional activator at this site, driving constitutively higher PAI-1 expression. The 5G allele binds both an activator and a repressor, resulting in lower net PAI-1 transcription. The functional consequence is directly measurable: 4G/4G homozygotes have substantially higher circulating PAI-1 activity than 5G/5G carriers.

The effect is amplified during inflammation. Yatsenko et al. 2024¹¹ Yatsenko et al. 2024
Yatsenko T et al. The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction. Front Immunol. 2024 demonstrated that IL-1β preferentially upregulates PAI-1 in 4G/4G endothelial cells, with NFκB signaling significantly more active in 4G/4G peripheral blood mononuclear cells during acute systemic inflammation — explaining why the 4G genotype's effect on thrombotic risk is most pronounced in high-inflammation states.

The Evidence

Venous thromboembolism (VTE): Wang et al. 2014 — meta-analysis of 34 studies, 3,561 VTE cases and 5,693 controls²² Wang et al. 2014 — meta-analysis of 34 studies, 3,561 VTE cases and 5,693 controls
Wang J et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res. 2014;134(6):1241-8 found a dominant-model OR of 1.32 (95% CI 1.13-1.54) for VTE overall, rising to OR 1.60 (95% CI 1.24-2.06) specifically for deep vein thrombosis. In Asian populations the effect was strongest at OR 2.08. Critically, when the 4G allele co-occurred with Factor V Leiden, the VTE risk amplified to OR 1.72. An earlier meta-analysis by Tsantes et al. 2007 — 18 studies, 2,644 cases³³ Tsantes et al. 2007 — 18 studies, 2,644 cases
Tsantes AE et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis: a meta-analysis. Thromb Haemost. 2007;97(6):907-13 found a per-allele OR of 1.15 for VTE without additional risk factors, rising to OR 1.83 in individuals with other genetic thrombophilias.

Coronary artery disease: The largest analysis — Ye et al. 2006 — 66,155 CAD cases and 91,307 controls across 191 studies⁴⁴ Ye et al. 2006 — 66,155 CAD cases and 91,307 controls across 191 studies
Ye Z et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006;367(9511):651-8 — found a per-allele RR of 1.06 (95% CI 1.02-1.10) for coronary disease. The authors noted evidence of publication bias, suggesting the true effect is real but modest. A Mendelian randomization meta-analysis by Nikolopoulos et al. 2014⁵⁵ Nikolopoulos et al. 2014
Nikolopoulos GK et al. The association between PAI-1 levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clin Chem Lab Med. 2014;52(7):937-44 confirmed OR 1.09 for MI specifically and identified elevated triglycerides and cholesterol as part of the causal pathway from 4G allele to MI.

Pregnancy complications: Zhao et al. 2013 — 11 studies, 1,297 preeclampsia cases⁶⁶ Zhao et al. 2013 — 11 studies, 1,297 preeclampsia cases
Zhao L et al. Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism and pre-eclampsia. Mol Hum Reprod. 2013;19(3):136-43 found OR 1.36 (95% CI 1.13-1.64) for preeclampsia under the recessive model, with low heterogeneity (I²=20%). For recurrent pregnancy loss, Wen et al. 2023 — 124 articles, 17,278 RPL cases⁷⁷ Wen et al. 2023 — 124 articles, 17,278 RPL cases
Wen Y et al. Thrombophilic gene polymorphisms and recurrent pregnancy loss: a systematic review and meta-analysis. J Assist Reprod Genet. 2023 found dominant OR 1.67 and recessive OR 1.80 — among the strongest thrombophilia associations with pregnancy loss.

Interaction with Factor V Leiden: Sundquist et al. 2015 — 1,069 Swedish VTE patients, 9.8-year follow-up⁸⁸ Sundquist et al. 2015 — 1,069 Swedish VTE patients, 9.8-year follow-up
Sundquist K et al. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence. Thromb Haemost. 2015 found that 4G allele alone did not independently predict VTE recurrence, but the combination of 4G allele plus Factor V Leiden produced HR 2.3 (95% CI 1.5-3.3) for recurrence after stopping anticoagulation — more than doubling the risk.

Practical Actions

For 4G/4G homozygotes, the suppressed fibrinolytic capacity warrants targeted monitoring of the coagulation-fibrinolysis axis: D-dimer, PAI-1 activity, and fibrinogen are the specific biomarkers elevated by this genotype. The 4G/4G genotype is particularly actionable in the context of combined thrombophilia testing — knowing whether Factor V Leiden or prothrombin G20210A co-occurs changes the recurrence risk calculation substantially. For women planning pregnancy, the 4G/4G genotype is a recognized contributor to preeclampsia and recurrent pregnancy loss risk, warranting preconception thrombophilia evaluation.

Long-chain omega-3 fatty acids (EPA/DHA) have been shown in multiple trials to lower PAI-1 activity — a genotype-specific intervention that directly addresses the elevated PAI-1 expression caused by the 4G allele. This effect is distinct from omega-3's general cardiovascular benefits and is mechanistically tied to the PAI-1 pathway.

Interactions

The PAI-1 4G allele interacts additively with Factor V Leiden (rs6025, F5 R506Q). Factor V Leiden reduces anticoagulant activity by making Factor Va resistant to inactivation by protein C; PAI-1 4G reduces fibrinolytic activity by suppressing tPA. These two defects operate on different limbs of hemostasis — anticoagulation and clot dissolution — and compound to produce substantially higher recurrent VTE risk than either alone. The Sundquist 2015 prospective cohort specifically documented the HR 2.3 interaction.

The 4G allele also interacts with prothrombin G20210A (rs1799963, F2) in the prothrombotic direction. While Sundquist 2015 did not find the prothrombin interaction as statistically robust as the Factor V Leiden interaction, the biological rationale (reduced clot dissolution + elevated thrombin generation) supports combined thrombophilia panel testing when either variant is identified.

In diabetic populations, the 4G allele's effects on vascular complications are amplified, with a meta-analysis of 51 case-control studies finding OR 2.46 for nephropathy in Asian diabetics — likely because hyperglycemia further upregulates PAI-1 expression at the 4G promoter.